Find Locations
For hours, walk-ins and appointments.
Neurological
Biomarker-driven
Development
Expedite delivery of your life-changing therapies to address neurodegenerative disorders with industry-leading testing and biopharma solutions that help you discover, develop and deliver your next breakthrough.
Labcorp offers comprehensive global testing to support all aspects of your neurodegenerative therapeutic development
Innovative Biomarker Testing
including pTau217, GFAP, NfL and Aβ 42/40
Deep Therapeutic Expertise
across neurodegenerative diseases like Alzheimer's, Parkinson's and more
Comprehensive Clinical Trial Testing
from biomarker discovery to companion diagnostic commercialization
Labcorp has extensive experience helping clients develop promising new therapies for neurodegenerative disease, supporting 100% of the 2023 FDA-approved therapies.
Key Biomarkers for Neurodegenerative Therapy Development:
| Biomarker | Associated Diseases | ||||||||||
| NfL | Neurodegeneration: MS, ALS, AD, PD, FTD (frontotemporal dementia), HAND (HIV associated neurocognitive disorder), COVID-19 associated neurological disorders, concussion/mTBI | ||||||||||
| GFAP | Neurodegeneration: MS, AD, NMOSD (neuromyelitis optica spectrum disorder), COVID-19 associated neurological disorders, concussion/mTBI | ||||||||||
| pTau217 | AD | ||||||||||
| pTau181 | AD | ||||||||||
| Total tau | Tauopathies: AD, FTD with Parkinsons (PD), PSP (progressive supranuclear palsy), HAND, concussion/mTBI | ||||||||||
| Neuro 3-plex: Amyloid beta (1-42), Amyloid beta (1-40), total tau | AD, HAND | ||||||||||
| Neuro 4-plex E: Amyloid beta (1-42), Amyloid beta (1-40), NfL and GFAP | AD | ||||||||||
| Neuro 4-plex A: NfL, GFAP, Total Tau, UCH-L1 | Concussion/mTBI | ||||||||||
| a-synuclein | PD, AD | ||||||||||
| Amyloid beta (1-40) | AD | ||||||||||
| Amyloid beta (1-42) | AD | ||||||||||
| Amyloid beta 42/40 | AD | ||||||||||
| pTau231 | AD | ||||||||||
| Cytokine 3-plex: IL-6, TNFa, IL-10 | AD (inflammation) | ||||||||||
One partner to achieve your next Alzheimer’s advancement
Check out our Alzheimer’s-specific biomarker offerings.
Leverage Labcorp’s deep knowledge supporting 90+ Alzheimer’s disease protocols–in 45+ countries with 96,000+ patients–in the last 5 years alone
Access holistic and specialized neurology expertise for support from strategy to lab with our Biomarker Solution Center and global translational biomarker scientists
Experience Alzheimer's clinical trial testing delivered by a global laboratory network with critical sample management and logistics capabilities
Let's discuss your program to determine how we can help accelerate you neurodegenerative therapy innovation.
Explore More Neurodegenerative Capabilities
ALS, Ataxias, & Huntington's
Genetics can play a significant role in the development of certain neurodegenerative diseases. In some cases, genetic testing may help confirm a diagnosis.
Alzheimer's
Finding a way to diagnose Alzheimer's earlier and easier is a key goal for Labcorp.
Muscular Dystrophy
Characterized by progressive muscle loss and weakness, our tests can detect the genetic mutations that cause the most common forms.
Multiple Sclerosis
While no single test can diagnose multiple sclerosis, lab tests may help doctors rule out other diseases and confirm a diagnosis.